BR112018016133A2 - aglutinantes de max como moduladores de myc e usos dos mesmos - Google Patents

aglutinantes de max como moduladores de myc e usos dos mesmos

Info

Publication number
BR112018016133A2
BR112018016133A2 BR112018016133A BR112018016133A BR112018016133A2 BR 112018016133 A2 BR112018016133 A2 BR 112018016133A2 BR 112018016133 A BR112018016133 A BR 112018016133A BR 112018016133 A BR112018016133 A BR 112018016133A BR 112018016133 A2 BR112018016133 A2 BR 112018016133A2
Authority
BR
Brazil
Prior art keywords
formula
myc
binders
max
modulators
Prior art date
Application number
BR112018016133A
Other languages
English (en)
Inventor
Chen Andrew
N Koehler Angela
Vijith Neel Dylan
Stefan Eric
Caballero Francisco
L Evans Helen
B Struntz Nicholas
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of BR112018016133A2 publication Critical patent/BR112018016133A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção fornece os compostos de fórmula (i'), fórmula (i), fórmula (ii), fórmula (ii-a), fórmula (iii), e fórmula (iv). os compostos descritos aqui são aglutinantes de max e/ou moduladores de myc, mad ou mxi1 (por exemplo, inibidores de myc, mad ou mxi1), e podem ser úteis na tratamento de um indivíduo com uma doença associada com myc, tal como doenças proliferativas (por exemplo, câncer). são também fornecidos na presente invenção composições farmacêuticas e kits incluindo os compostos descritos aqui, bem como métodos de usos e usos dos compostos, composições e kits.
BR112018016133A 2016-02-16 2017-02-16 aglutinantes de max como moduladores de myc e usos dos mesmos BR112018016133A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662295996P 2016-02-16 2016-02-16
PCT/US2017/018162 WO2017143059A1 (en) 2016-02-16 2017-02-16 Max binders as myc modulators and uses thereof

Publications (1)

Publication Number Publication Date
BR112018016133A2 true BR112018016133A2 (pt) 2019-01-02

Family

ID=58191662

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016133A BR112018016133A2 (pt) 2016-02-16 2017-02-16 aglutinantes de max como moduladores de myc e usos dos mesmos

Country Status (11)

Country Link
US (2) US10106555B2 (pt)
EP (1) EP3416950A1 (pt)
JP (1) JP2019505548A (pt)
KR (1) KR20180107261A (pt)
CN (1) CN109071456A (pt)
AU (1) AU2017221422A1 (pt)
BR (1) BR112018016133A2 (pt)
CA (1) CA3012846A1 (pt)
MX (1) MX2018009913A (pt)
RU (1) RU2018132559A (pt)
WO (1) WO2017143059A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180107261A (ko) 2016-02-16 2018-10-01 메사추세츠 인스티튜트 오브 테크놀로지 Myc 조정제로서의 MAX 결합제 및 그의 용도
CN112601741A (zh) * 2018-07-09 2021-04-02 斯克里普斯研究学院 用于myc抑制的改进化合物
CN111274691A (zh) * 2020-01-16 2020-06-12 西安交通大学 一种分析预测max相材料可形成能力的方法
CA3171979A1 (en) 2020-03-27 2021-09-30 Josep Bassaganya-Riera Plxdc2 ligands
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02191695A (ja) 1989-01-20 1990-07-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02194085A (ja) 1989-01-24 1990-07-31 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02196887A (ja) 1989-01-26 1990-08-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02208392A (ja) 1989-02-08 1990-08-17 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02222488A (ja) 1989-02-23 1990-09-05 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227489A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227490A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227491A (ja) 1989-03-01 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02242882A (ja) 1989-03-16 1990-09-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247280A (ja) 1989-03-20 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247282A (ja) 1989-03-22 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255794A (ja) 1989-03-29 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255793A (ja) 1989-03-30 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
US5965574A (en) 1996-08-13 1999-10-12 Chen; Yuhpyng Liang Heteroaryl amines as novel acetylcholinesterase inhibitors
JPH08231541A (ja) 1995-03-01 1996-09-10 Nippon Soda Co Ltd イミダゾリン誘導体および除草剤
AU6331099A (en) 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1352650B1 (en) 2000-12-18 2012-03-07 Institute of Medicinal Molecular Design, Inc. Inhibitors against the production and release of inflammatory cytokines
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
JP2003057783A (ja) 2001-08-21 2003-02-26 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075955A (ja) 2001-09-03 2003-03-12 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075957A (ja) 2001-09-07 2003-03-12 Konica Corp スケイル模様のない光熱写真画像形成材料
EP1429763B1 (en) 2001-09-14 2007-05-30 Novo Nordisk A/S NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
US20050042674A9 (en) 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
GB2387172A (en) 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
JP2006500399A (ja) 2002-04-30 2006-01-05 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネルブロッカーとしての、アリール−結合−アリール置換された、チアゾリジン−ジオンおよびオキサゾリジン−ジオン
JP4211433B2 (ja) 2002-08-14 2009-01-21 三菱化学株式会社 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
US7777051B2 (en) 2003-05-13 2010-08-17 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
ES2530972T3 (es) 2003-09-12 2015-03-09 Elixir Pharmaceuticals Inc Métodos de tratamiento de trastornos
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
WO2005033090A1 (ja) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited 芳香族化合物
WO2006005683A1 (en) 2004-07-09 2006-01-19 Novo Nordisk A/S Phamaceutical preparations comprising insulin
JP2006084592A (ja) 2004-09-14 2006-03-30 Fuji Photo Film Co Ltd 感光性組成物
DE602005018911D1 (de) 2005-07-20 2010-03-04 Aventis Pharma Sa 1,4-Dihydropyridine-kondensierte Heterocyclen Verfahren zu deren Herstellung sowie Verwendung und Zusammensetzungen dergleichen
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
JP4931434B2 (ja) 2006-02-14 2012-05-16 株式会社ダイセル アミノ基含有アダマンタン誘導体とその製造方法
WO2007146712A2 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
US20100009969A1 (en) 2006-07-27 2010-01-14 Ucb Pharma, S.A. Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20100292188A1 (en) 2008-01-24 2010-11-18 Ucb Pharma S.A. Compounds Comprising A Cyclobutoxy Group
US8133695B2 (en) 2008-02-28 2012-03-13 Life Technologies Corporation Fluorescence polarization hERG assay
MX2011004953A (es) 2008-11-10 2011-12-14 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
EP2365969B1 (en) 2008-11-20 2017-03-22 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Novel anti-biofilm agents
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
JP5046213B2 (ja) 2009-03-12 2012-10-10 独立行政法人科学技術振興機構 光学活性アルコール化合物の製法
JP2013511562A (ja) 2009-11-24 2013-04-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
EP2509602B9 (en) 2009-12-04 2017-11-01 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
RU2635662C2 (ru) 2010-09-10 2017-11-15 Сионоги Энд Ко., Лтд. Конденсированное с гетерокольцом имидазольное производное, обладающее активирующим амрк действием
US9537111B2 (en) 2011-05-11 2017-01-03 Idemitsu Kosan Co., Ltd. Compound, material for organic electroluminescence device, and organic electroluminescence device
CN103649067A (zh) 2011-09-13 2014-03-19 出光兴产株式会社 稠合杂芳香族衍生物、有机电致发光元件用材料及使用其的有机电致发光元件
JP6653573B2 (ja) 2012-05-22 2020-02-26 トラスティーズ・オブ・ダートマウス・カレッジ シクロアルカニル［ｂ］インドール、シクロアルカニル［ｂ］ベンゾフラン、シクロアルカニル［ｂ］ベンゾチオフェンを合成するための方法、化合物および使用の方法
CN107501275B (zh) * 2012-12-07 2019-11-22 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物
BR112015020281B1 (pt) 2013-02-28 2020-04-22 Sumitomo Chemical Co composto heterocíclico fundido, agente e método para o controle de pragas
US8901164B2 (en) * 2013-03-07 2014-12-02 University Of Maryland, Baltimore Amphipathic and other double-sided alpha-helix mimetics based on a 1,2-diphenylacetylene scaffold
WO2014159837A1 (en) 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
US9242944B2 (en) * 2013-03-27 2016-01-26 University Of Maryland, Baltimore Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability
AU2014363935A1 (en) * 2013-12-11 2016-06-02 Kim D. Janda Small molecule c-Myc inhibitors
AU2015360416A1 (en) 2014-12-10 2017-06-08 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
KR20180107261A (ko) 2016-02-16 2018-10-01 메사추세츠 인스티튜트 오브 테크놀로지 Myc 조정제로서의 MAX 결합제 및 그의 용도

Also Published As

Publication number Publication date
EP3416950A1 (en) 2018-12-26
RU2018132559A (ru) 2020-03-17
US20190144466A1 (en) 2019-05-16
WO2017143059A1 (en) 2017-08-24
KR20180107261A (ko) 2018-10-01
AU2017221422A1 (en) 2018-08-16
MX2018009913A (es) 2018-11-29
US10865213B2 (en) 2020-12-15
CA3012846A1 (en) 2017-08-24
US10106555B2 (en) 2018-10-23
JP2019505548A (ja) 2019-02-28
US20170233405A1 (en) 2017-08-17
CN109071456A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
BR112018016133A2 (pt) aglutinantes de max como moduladores de myc e usos dos mesmos
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112022007627A2 (pt) Compostos moduladores do glp-1r
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112018015413A2 (pt) inibidores de indoleamina-2,3-dioxigenase (ido)
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
BR112016002496A2 (pt) composto de fórmula i, composição farmacêutica, método para inibição de kdm1a, método para tratamento de uma doença mediada por globina, método para atingir um efeito em um paciente, e, método para inibir pelo menos uma função de kdm1a
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
BR112022002698A2 (pt) Compostos de imidazolil pirimidinilamina como inibidores de cdk2
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
BR112016028219A2 (pt) composto, método de tratamento ou prevenção do câncer, de uma doença infecciosa, ou de uma doença designada por aberração de metabolismo de energia celular em um indivíduo, método de tratamento ou prevenção de leucemia, câncer de pulmão de não pequenas células, carcinoma hepatocelular, ou glioblastomas em um indivíduo, método de tratamento de uma doença ou distúrbio em um indivíduo, composição farmacêutica e processo para obtenção de um composto de fórmula (i)
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
BR112016022069A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112016030730A8 (pt) composto
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]